AXS-05 has demonstrated clinical superiority over Bupropion with no psychotomimetic side effects nor somnolence.
This alone is enough to justify AXSM's $800 million valuation.
AXS-05's other indications, however, may not possess feasible investigational goals.
Nonetheless, the company's Phase 3 data release for all 3 of its drug candidates due by the end of FY2019 will likely serve as major bullish catalysts.
Axsome Therapeutics' (NASDAQ:AXSM) is a small-cap biotech company specializing in treating psychiatric and central nervous system disorders. The company's most promising drug candidate, AXS-05, is being investigated for 3 indications, with